Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 in Major Depressive Disorder
NCT03078322Phase 2Completed
- Sponsor
- Vistagen Therapeutics
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 4-chlorokynurenine in major depressive disorder (MDD), sponsored by Vistagen Therapeutics. Started Mar 2018; status: completed.
02
Drugs
4-chlorokynurenine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03078322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078322.